[go: up one dir, main page]

MX374354B - Método de curación de heridas. - Google Patents

Método de curación de heridas.

Info

Publication number
MX374354B
MX374354B MX2018001684A MX2018001684A MX374354B MX 374354 B MX374354 B MX 374354B MX 2018001684 A MX2018001684 A MX 2018001684A MX 2018001684 A MX2018001684 A MX 2018001684A MX 374354 B MX374354 B MX 374354B
Authority
MX
Mexico
Prior art keywords
wound healing
healing method
wound
administering
treating
Prior art date
Application number
MX2018001684A
Other languages
English (en)
Other versions
MX2018001684A (es
Inventor
MAMMEN Anup OOMEN
M R Jagannath
M V Venkataranganna
Somesh Baggavalli
Original Assignee
Connexios Life Sciences Pvt Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Connexios Life Sciences Pvt Ltd filed Critical Connexios Life Sciences Pvt Ltd
Publication of MX2018001684A publication Critical patent/MX2018001684A/es
Publication of MX374354B publication Critical patent/MX374354B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/46—Ingredients of undetermined constitution or reaction products thereof, e.g. skin, bone, milk, cotton fibre, eggshell, oxgall or plant extracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Botany (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención se refiere a un método para tratar una herida, que comprende administrar a un sujeto que lo necesita una cantidad terapéuticamente eficaz de un compuesto de aza adamantano de acuerdo con Fórmula (I), o una sal farmacéuticamente aceptable del mismo.
MX2018001684A 2015-08-11 2016-08-11 Método de curación de heridas. MX374354B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN4178CH2015 2015-08-11
PCT/IN2016/050270 WO2017025988A1 (en) 2015-08-11 2016-08-11 Method of wound healing

Publications (2)

Publication Number Publication Date
MX2018001684A MX2018001684A (es) 2018-05-17
MX374354B true MX374354B (es) 2025-03-06

Family

ID=57137206

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018001684A MX374354B (es) 2015-08-11 2016-08-11 Método de curación de heridas.

Country Status (13)

Country Link
US (1) US10328063B2 (es)
EP (1) EP3349752B1 (es)
JP (1) JP6953396B2 (es)
CN (1) CN107921034B (es)
AU (1) AU2016305746B2 (es)
BR (1) BR112018002763A2 (es)
CA (1) CA2993922A1 (es)
DK (1) DK3349752T3 (es)
ES (1) ES2891086T3 (es)
HK (1) HK1254325A1 (es)
MX (1) MX374354B (es)
WO (2) WO2017025989A1 (es)
ZA (1) ZA201800600B (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019162928A1 (en) * 2018-02-26 2019-08-29 Fidia Farmaceutici S.P.A. Multilayer composite material
EP3860998B1 (en) 2018-10-05 2023-12-27 Annapurna Bio Inc. Compounds and compositions for treating conditions associated with apj receptor activity
EP3821892A1 (en) 2019-11-12 2021-05-19 University of Leeds (s)-2-(1-(5-(cyclohexylcarbamoyl)-6-(propylthio)pyridin-2-yl)piperidin-3-yl) acetic acid for use in treating wounds

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0301888D0 (sv) * 2003-06-25 2003-06-25 Biovitrum Ab New use VII
CA2738453C (en) * 2008-10-23 2017-07-04 Boehringer Ingelheim International Gmbh Urea derivatives of substituted nortropanes, medicaments containing such compounds and their use
WO2013111150A1 (en) * 2011-12-22 2013-08-01 Connexios Life Sciences Pvt. Ltd. Derivatives of aza adamantane and uses thereof

Also Published As

Publication number Publication date
JP6953396B2 (ja) 2021-10-27
AU2016305746B2 (en) 2021-10-07
CN107921034B (zh) 2021-11-23
US20180221356A1 (en) 2018-08-09
BR112018002763A2 (pt) 2018-10-09
AU2016305746A1 (en) 2018-03-08
US10328063B2 (en) 2019-06-25
EP3349752B1 (en) 2021-06-30
HK1254325A1 (zh) 2019-07-19
WO2017025988A1 (en) 2017-02-16
ZA201800600B (en) 2018-11-28
EP3349752A1 (en) 2018-07-25
DK3349752T3 (da) 2021-09-27
CA2993922A1 (en) 2017-02-16
ES2891086T3 (es) 2022-01-26
MX2018001684A (es) 2018-05-17
CN107921034A (zh) 2018-04-17
JP2018522917A (ja) 2018-08-16
WO2017025989A1 (en) 2017-02-16

Similar Documents

Publication Publication Date Title
PH12018500041A1 (en) Substituted aza compoounds as irak-4 inhibitors
PH12015502075B1 (en) Treatment of cataplexy
MX377845B (es) Inhibidores de calicreína plasmática humana.
EA201791576A1 (ru) Ингибитор jak
MX2018006674A (es) Tratamiento de cancer usando 2-desoxi-2-fluoro-l-fucosa en combinacion con un inhibidor del punto de control.
CY1121710T1 (el) Παρεμβασεις με βαση την αγγειοποιητινη για τη θεραπεια της εγκεφαλικης ελονοσιας
PH12017500493A1 (en) Combination therapy
EA201690513A1 (ru) Комбинация ингибитора mek и ингибитора erk для применения в лечении гиперпролиферативных заболеваний
EA201892726A1 (ru) Дейтерированный палбоциклиб
EA201690039A1 (ru) Ингибиторы rorc2 и способы их применения
EA201591362A1 (ru) Соединения и способы лечения бактериальных инфекций
EA201692481A1 (ru) Комбинация, содержащая глюкокортикоид и edo-s101
EA201991253A1 (ru) Бензодиазолиевые соединения в качестве ингибиторов enac
EA201792264A1 (ru) Способы лечения воспалительных заболеваний
EA201991688A1 (ru) Фармацевтические комбинации для лечения рака
EA201790687A1 (ru) Хинолинкарбоксамиды для применения в лечении множественной миеломы
EA201690763A1 (ru) Лечение рака поджелудочной железы
PH12014502065A1 (en) Vesicular formulations
MX374354B (es) Método de curación de heridas.
EA201690446A1 (ru) Лечение множественной миеломы
MY198753A (en) Treatment of androgen deprivation therapy associated symptoms
BR112016014099A2 (pt) método de tratamento de feridas
MX2018006631A (es) Compuesto para uso en la prevencion y tratamiento de enfermedades neurodegenerativas.
EA201690214A1 (ru) Способ лечения гипертрофической кардиомиопатии
TR201906539T4 (tr) Mentol, Linalool ve/veya Icilin Kullanarak Beyin Travması ve İnmelerden Kaynaklanan Non-İnflamatuar Nöron Hasarının Tedavisi veya Önlenmesi.

Legal Events

Date Code Title Description
FG Grant or registration